MARKET

LNTH

LNTH

Lantheus Hldg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.47
-0.45
-3.48%
After Hours: 12.47 0 0.00% 16:00 09/21 EDT
OPEN
12.57
PREV CLOSE
12.92
HIGH
12.79
LOW
12.05
VOLUME
453.88K
TURNOVER
--
52 WEEK HIGH
27.12
52 WEEK LOW
8.67
MARKET CAP
833.16M
P/E (TTM)
41.31
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced
Business Wire · 09/03 13:00
Healthcare Dashboard For August
A dashboard with metrics of value, quality and momentum by industries.Value and quality scores relative to historical averages.Evolution since last month.The best and the worst industries in value, quality and momentum.
Seekingalpha · 08/18 15:59
FDA OKs Lantheus ultrasound imaging agent
The FDA approves Lantheus's ([[LNTH]] -0.3%) VIALMIX RFID an activation device for DEFINITY injectable suspension, an intravenous ultrasound enhancing agent.The RFID tag, which is affixed to the vial label, enables controlling the activation rate and
Seekingalpha · 08/12 15:03
Lantheus shares are trading higher after the company announced that the FDA approved its VIALMIX RFID Device for DIGNITY.
Benzinga · 08/12 14:48
Lantheus Holdings, Inc. Announces FDA Approval Of VIALMIX RFID Device For DEFINITY
Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and
Benzinga · 08/12 12:02
Lantheus Holdings, Inc.'s (LNTH) CEO Mary Anne Heino on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/31 10:51
Lantheus Holdings Q2 EPS $0.10 Beats $0.05 Estimate, Sales $66.00M Beat $56.62M Estimate
Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.05 by 100 percent. This is a 62.96 percent decrease over earnings of $0.27 per share from the
Benzinga · 07/30 11:07
Lantheus EPS beats by $0.02, beats on revenue
Seeking Alpha · 07/30 11:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LNTH stock price target is 21.00 with a high estimate of 29.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 317
Institutional Holdings: 63.03M
% Owned: 94.34%
Shares Outstanding: 66.81M
TypeInstitutionsShares
Increased
80
6.70M
New
65
-795.12K
Decreased
68
7.22M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.45%
Healthcare Equipment & Supplies
-1.43%
Key Executives
Non-Executive Chairman/Independent Director
Brian Markison
President/Chief Executive Officer/Director
Mary Heino
Chief Financial Officer/Treasurer
Robert Marshall
Chief Operating Officer/Senior Vice President
John Bolla
Senior Vice President/General Counsel
Michael Duffy
Senior Vice President
Etienne Montagut
Senior Vice President
Simon Robinson
Senior Vice President
Carol Walker
Other
Paul Blanchfield
Other
Istvan Molnar
Independent Director
Gerard Ber
Independent Director
James Clemmer
Independent Director
Samuel Leno
Independent Director
Heinz Mausli
Independent Director
Julie McHugh
Independent Director
Gary Pruden
Independent Director
Frederick Robertson
Independent Director
James Thrall
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average LNTH stock price target is 21.00 with a high estimate of 29.00 and a low estimate of 16.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LNTH
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Lantheus Holdings Inc stock information, including NASDAQ:LNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LNTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LNTH stock methods without spending real money on the virtual paper trading platform.